Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: A 12 week, phase 3 study

Current Medical Research and Opinion

Volumn 30, Issue 9, 2014, Pages 1883-1893

  Gibofsky, Allan ^a   Hochberg, Marc C ^b   Jaros, Mark J ^c   Young, Clarence L ^d  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Summit Analytical   (United States)

^d Iroko Pharmaceuticals   (United States)

Author keywords

Chronic pain; Diclofenac capsules; NSAID; Osteoarthritis; Submicron

Indexed keywords

DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MEDICINAL CHEMISTRY; MIDDLE AGED; MULTICENTER STUDY; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 84906833378     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.946123     Document Type: Article

References (48)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
2. Hochberg MC. Prognosis of osteoarthritis. Ann Rheum Dis 1996;55:685-8
3. Hadler NM. Knee pain is the malady-not osteoarthritis. Ann Intern Med 1992;116:598-9
4. Voltaren XR (diclofenac sodium extended-release): US prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/voltaren-xr.pdf [Last accessed 27 December 2013]
5. McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10: e1001388
6. Lewis SC, Langman MJ, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54:320-6
7. Riera-Guardia N, Castellsague J, Calingaert B, et al. The SOS Project: nonsteroidal anti-inflammatory drugs and upper gastrointenstinal complications. Meta-Analysis of epidemiological studies. Presented at 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, August 2010, Brighton, United Kingdom
8. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79
9. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81
10. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098
11. Schmidt M, Christiansen CF, Mehnert F, et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based casecontrol study. BMJ 2011;343:d3450
12. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32(3 Suppl 1):33-42
13. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13-24S
14. US Food and Drug Administration. Public Health Advisory-FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). 2005. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm150314.htm [Last accessed 16 May 2013]
15. Iroko Pharmaceuticals LLC. Unpublished data. 2012
16. Zorvolex (diclofenac): US prescribing information. Philadelphia, PA: Iroko Pharmaceuticals LLC, 2013. Available at: https://www.iroko.com/wp-content/ uploads/2013/10/Zorvolex-PI-10-18-2013.pdf [Last accessed 24 February 2014]
17. Gibofsky A, Silberstein S, Argoff C, et al. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Postgrad Med 2013;125:130-8
18. Kellgren J, Lawrence J. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502
19. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000;284:3043-5
20. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21
21. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355-60
22. Fairclough DL. Design and analysis of quality of life studies in clinical trials. In Interdisciplinary Statistics series. Boca Raton, FL: Chapman & Hall/CRC Press, 2002
23. Silverman DG, O'Connor TZ, Brull SJ. Integrated assessment of pain scores and rescue morphine use during studies of analgesic efficacy. Anesth Analg 1993;77:168-70
24. Hawker GA, Davis AM, French MR, et al. Development and preliminary psychometric testing of a new OA pain measure-an OARSI/OMERACT initiative. Osteoarthritis Cartilage 2008;16:409-14
25. Argoff CE. Recent developments in the treatment of osteoarthritis with NSAIDs. Curr Med Res Opin 2011;27:1315-27
26. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81
27. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62
28. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476-99
29. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31
30. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331-46
31. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I-evidence assessment. Pain Physician 2012;15(3 Suppl):S1-65
32. Takkouche B, Montes-Martinez A, Gill SS, et al. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 2007;30:171-84
33. Gomes T, Redelmeier DA, Juurlink DN, et al. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med 2013;173:196-201
34. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174:1589-94
35. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006;74:1347-54
36. Moallem SA, Balali-Mood K, Balali-Mood M. Opioids and opiates. In: Mozayani A, Raymon L, eds. Handbook of Drug Interactions. New York, NY: Humana Press, 2012:159-91
37. Hochberg MC, Fort JG, Svensson O, et al. Fixed-dose combination of entericcoated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin 2011;27:1243-53
38. Gigante A, Tagarro I. Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole. Clin Drug Investig 2012;32:221-33
39. Laine L, Kivitz AJ, Bello AE, et al. Double-blind randomized trials of singletablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol 2012;107:379-86
40. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000;284:1247-55
41. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8
42. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004;329:324
43. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2012;9:CD007400.
44. Arnstein PM. Evolution of topical NSAIDs in the guidelines for treatment of osteoarthritis in elderly patients. Drugs Aging 2012;29:523-31.
45. McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-18
46. Emery P, Koncz T, Pan S, Lowry S. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study. Clin Ther 2008;30:70-83
47. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal antiinflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med 2000;9:1124-34
48. Trijau S, Avouac J, Escalas C, et al. Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a metaanalysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010;18:1012-18